BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, Umscheid CA. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect 2018;24:361-8. [PMID: 28882727 DOI: 10.1016/j.cmi.2017.08.028] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, Loeches B, Lopez-Cortés LE, Fariñas MC, Fernández-Roldan C, Javier-Martinez R, Muñoz P, Arenas-Miras MDM, Martínez-Marcos FJ, Miró JM, Herrero C, Bereciartua E, De Jesus SE, Pasquau J. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob 2019;18:30. [PMID: 31629409 DOI: 10.1186/s12941-019-0329-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
2 Almangour TA, Perry GK, Terriff CM, Alhifany AA, Kaye KS. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility. Diagnostic Microbiology and Infectious Disease 2019;93:213-8. [DOI: 10.1016/j.diagmicrobio.2018.10.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
3 Principi N, Argentiero A, Neglia C, Gramegna A, Esposito S. New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics. Pharmaceuticals (Basel) 2020;13:E333. [PMID: 33113966 DOI: 10.3390/ph13110333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Petrakis V, Panagopoulos P, Papanas N. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections. Int J Low Extrem Wounds 2020;19:236-41. [PMID: 32500744 DOI: 10.1177/1534734620921677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tessier JM, Sanders J, Sartelli M, Ulrych J, De Simone B, Grabowski J, Buckman S, Duane TM. Necrotizing Soft Tissue Infections: A Focused Review of Pathophysiology, Diagnosis, Operative Management, Antimicrobial Therapy, and Pediatrics. Surg Infect (Larchmt) 2020;21:81-93. [PMID: 31584343 DOI: 10.1089/sur.2019.219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Spinicci M, Corti G. Septic arthritis in the antimicrobial stewardship era. Intern Emerg Med 2020;15:567-9. [PMID: 32236890 DOI: 10.1007/s11739-020-02302-6] [Reference Citation Analysis]
7 Béraud G, Maupetit JC, Darras A, Vimont A, Blachier M. Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals. Infect Dis Ther 2021. [PMID: 34913137 DOI: 10.1007/s40121-021-00577-6] [Reference Citation Analysis]
8 Gunderson CG, Cherry BM, Fisher A. Do Patients with Cellulitis Need to be Hospitalized? A Systematic Review and Meta-analysis of Mortality Rates of Inpatients with Cellulitis. J Gen Intern Med 2018;33:1553-60. [PMID: 30022408 DOI: 10.1007/s11606-018-4546-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 Hsu CK, Chen CY, Chen WC, Chao CM, Lai CC. Clinical efficacy and safety of novel lipoglycopeptides in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-10. [PMID: 34550853 DOI: 10.1080/14787210.2022.1984880] [Reference Citation Analysis]
10 Wang Y, Wang J, Wang R, Li Y, Cai Y. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections. J Glob Antimicrob Resist 2021;24:72-80. [PMID: 33279683 DOI: 10.1016/j.jgar.2020.11.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Gatti M, Andreoni M, Pea F, Viale P. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. Drug Des Devel Ther 2021;15:3349-78. [PMID: 34376971 DOI: 10.2147/DDDT.S313756] [Reference Citation Analysis]
12 Howard-Anderson J, Pouch SM, Sexton ME, Mehta AK, Smith AL, Lyon GM 3rd, Friedman-Moraco R. Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report. Open Forum Infect Dis 2019;6:ofz235. [PMID: 31660392 DOI: 10.1093/ofid/ofz235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
13 Yushchuk O, Andreo-Vidal A, Marcone GL, Bibb M, Marinelli F, Binda E. New Molecular Tools for Regulation and Improvement of A40926 Glycopeptide Antibiotic Production in Nonomuraea gerenzanensis ATCC 39727. Front Microbiol 2020;11:8. [PMID: 32038594 DOI: 10.3389/fmicb.2020.00008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
14 Ma YX, Wang CY, Li YY, Li J, Wan QQ, Chen JH, Tay FR, Niu LN. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections. Adv Sci (Weinh) 2020;7:1901872. [PMID: 31921562 DOI: 10.1002/advs.201901872] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 18.3] [Reference Citation Analysis]
15 de Pablo-Miró M, Pujol-Ruiz S, Iftimie S, Arenas-Miras MDM, López-Montesinos I, Duran-Jordà X, Anglès A, Grau S, Horcajada JP. Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. Antibiotics (Basel) 2021;10:1296. [PMID: 34827234 DOI: 10.3390/antibiotics10111296] [Reference Citation Analysis]
16 Jame W, Basgut B, Abdi A. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis. PLoS One 2021;16:e0260539. [PMID: 34843561 DOI: 10.1371/journal.pone.0260539] [Reference Citation Analysis]
17 Almarzoky Abuhussain SS, Goodlet KJ, Nailor MD, Nicolau DP. Optimizing skin and skin structure infection outcomes: considerations of cost of care. Expert Rev Pharmacoecon Outcomes Res 2018;18:235-44. [PMID: 29521147 DOI: 10.1080/14737167.2018.1450142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Rimpiläinen T, Nunes A, Calado R, Fernandes AS, Andrade J, Ntungwe E, Spengler G, Szemerédi N, Rodrigues J, Gomes JP, Rijo P, Candeias NR. Increased antibacterial properties of indoline-derived phenolic Mannich bases. Eur J Med Chem 2021;220:113459. [PMID: 33915373 DOI: 10.1016/j.ejmech.2021.113459] [Reference Citation Analysis]
19 Andreoni M, Bassetti M, Corrao S, De Rosa FG, Esposito V, Falcone M, Grossi P, Pea F, Petrosillo N, Tascini C, Venditti M, Viale P. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther 2021;19:1125-34. [PMID: 33682593 DOI: 10.1080/14787210.2021.1894130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sartelli M, Guirao X, Hardcastle TC, Kluger Y, Boermeester MA, Raşa K, Ansaloni L, Coccolini F, Montravers P, Abu-Zidan FM, Bartoletti M, Bassetti M, Ben-Ishay O, Biffl WL, Chiara O, Chiarugi M, Coimbra R, De Rosa FG, De Simone B, Di Saverio S, Giannella M, Gkiokas G, Khokha V, Labricciosa FM, Leppäniemi A, Litvin A, Moore EE, Negoi I, Pagani L, Peghin M, Picetti E, Pintar T, Pupelis G, Rubio-Perez I, Sakakushev B, Segovia-Lohse H, Sganga G, Shelat V, Sugrue M, Tarasconi A, Tranà C, Ulrych J, Viale P, Catena F. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg 2018;13:58. [PMID: 30564282 DOI: 10.1186/s13017-018-0219-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
21 Eckmann C, Tulkens PM. Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. J Antimicrob Chemother 2021;76:iv9-iv22. [PMID: 34849999 DOI: 10.1093/jac/dkab351] [Reference Citation Analysis]
22 Dretske D, Schulz L, Werner E, Sharp B, Pulia M. Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: A case series. Am J Emerg Med 2021;43:77-80. [PMID: 33545550 DOI: 10.1016/j.ajem.2021.01.050] [Reference Citation Analysis]
23 Hatlen TJ, Miller LG. Staphylococcal Skin and Soft Tissue Infections. Infect Dis Clin North Am 2021;35:81-105. [PMID: 33303329 DOI: 10.1016/j.idc.2020.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Simonetti O, Rizzetto G, Molinelli E, Cirioni O, Offidani A. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization. Ther Clin Risk Manag 2021;17:223-32. [PMID: 33790563 DOI: 10.2147/TCRM.S271445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Bartoszko JJ, Mertz D, Thabane L, Loeb M. Antibiotic therapy for skin and soft tissue infections: a protocol for a systematic review and network meta-analysis. Syst Rev 2018;7:138. [PMID: 30205844 DOI: 10.1186/s13643-018-0804-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Zhou D, Xie L, Wang Y, Wu S, Liu F, Zhang S, Liu R, Zhu L. Clinical Efficacy of Tonic Traditional Chinese Medicine Injection on Acute Cerebral Infarction: A Bayesian Network Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:8318792. [PMID: 33299456 DOI: 10.1155/2020/8318792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Durante-Mangoni E, Gambardella M, Iula VD, De Stefano GF, Corrado MF, Esposito V, Gentile I, Coppola N. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents 2020;56:106107. [PMID: 32721599 DOI: 10.1016/j.ijantimicag.2020.106107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Zhang Y, Wang Y, Van Driel ML, McGuire TM, Zhang T, Dong Y, Liu Y, Liu L, Hao R, Cao L, Xing J, Dong Y. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control 2019;8:72. [PMID: 31080587 DOI: 10.1186/s13756-019-0518-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Jia H, Li W, Hou T, Ma H, Yang Y, Wu A, Liu Y, Wen J, Yang H, Luo X, Xing Y, Zhang W, Wu Y, Ding L, Liu W, Lin L, Li Y, Chen M, Li L. The Attributable Direct Medical Cost of Healthcare Associated Infection Caused by Multidrug Resistance Organisms in 68 Hospitals of China. Biomed Res Int 2019;2019:7634528. [PMID: 30949509 DOI: 10.1155/2019/7634528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Poliseno M, Bavaro DF, Brindicci G, Luzzi G, Carretta DM, Spinarelli A, Messina R, Miolla MP, Achille TI, Dibartolomeo MR, Dell'Aera M, Saracino A, Angarano G, Favale S, D'Agostino C, Moretti B, Signorelli F, Taglietti C, Carbonara S. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections. Clin Drug Investig 2021;41:437-48. [PMID: 33884583 DOI: 10.1007/s40261-021-01028-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Lagi F, Ottino L, Mantengoli E, Distefano A, Corti G, Farese A, Dannaoui B, Ipponi A, Falai T, Rossolini GM, Bartoloni A, Bartalesi F. Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy. Eur J Clin Microbiol Infect Dis 2019;38:1781-5. [PMID: 31222396 DOI: 10.1007/s10096-019-03609-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Monteagudo-martínez N, Solís-garcía del Pozo J, Nava E, Ikuta I, Galindo M, Jordán J. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis. Expert Review of Anti-infective Therapy. [DOI: 10.1080/14787210.2021.1828865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
33 Zhang H, Zhou W, Wang J, Cai Y. Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis. J Glob Antimicrob Resist 2021;25:380-9. [PMID: 33989846 DOI: 10.1016/j.jgar.2021.04.013] [Reference Citation Analysis]